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Pulmonary arterial hypertension (PAH) is a chronic disorder that results in narrowing of the small 
pulmonary arteries and arterioles leading to elevation of pulmonary artery pressure, subsequent 
right ventricular failure, and if untreated, death. Advances in the treatment of PAH in the past 
two decades have dramatically improved symptoms and survival of the patients with PAH.The 
availability of new treatments has increased awareness of the condition.
Currently approved therapies for PAH include endothelin receptor antagonists, phosphodiesterase-5 
inhibitors, soluble guanylate cyclase stimulators, and prostacyclin pathway agents, that have 
been developed based on the assumption that PAH is caused by imbalance of vasoactive 
mediators of pulmonary arteries.
The description of the genetic features of PAH is accelerating, with novel mutations, such as 
potassium two-pore domain channel subfamily K member 3 (KCNK3) and caveolin 1 (CAV1), 
adding to the list of more established mutations in genes associated with bone morphogenetic 
protein receptor type 2 (BMPR2) or SMAD9.These insights have supported a paradigm shift 
in pathogenesis and treatment strategies from simply addressing the imbalance of vasoactive 
mediators observed in PAH towards tackling more directly the structural remodeling of the 
pulmonary artery.
In this symposium, the changing clinical and molecular landscape of PAH will be summarized. 
I will highlight novel therapeutic strategies that are in various stages of clinical development, 
targeting cell proliferation, metabolic, infl ammatory/immune and BMPR2 dysfunction, and the 
challenges around developing these treatments. 
